Description
The UK COVID-19 Pandemic Mitigation Products Market – 2020-2024 Report
On the backdrop of the need for essential medical products and services, a new market has emerged, the COVID-19 pandemic mitigation products market. This UK COVID-19 pandemic mitigation cumulative 2020-2024 market is worth $89 Billion (scenario B).
 |
(*) Market size is year and scenario dependent.
To adhere to our high standards of research, as nobody can forecast the future of the pandemic, we include in the report two scenarios:
- Optimistic scenario– assumes (among other things) that mass vaccination will commence by July 2021
- Conservative scenario– assumes (among other things) that no mass vaccination will be available until July 2024
The UK Healthcare, ICUs and Vaccines Outlay Statistics (2019)
 |
Sources: IMF, WHO, OECD, World Population Prospects (2019 Revision)
Why trust this report?
- The team which created this report was led by ex-executives of the medical industry and bio-security experts, who wrote this report with the COVID-19 industry executives in mind
- As the COVID-19 pandemic knowledge changes all the time, we update the report once a month
- The team has published since 2006 36 Pandemic related reports
- Team members managed since 1977 a medical systems & instrumentation subsidiary and factory in the UK
Bottom Line: While other COVID-19 reports are written (at best) by MBAs, this report is published by professionals for experts
2023 UK COVID-19 Pandemic Mitigation Market Share (Scenario A)
 |
(*) Market size is year and scenario dependent.
According to the report:
In some ways, Britain is more united than it has been for a long time. Brexit has been postponed. Party politics is all but halted, after Parliament voted to shut itself down on March to minimize the risk of transmission of COVID-19.
Growth in the number of COVID-19 cases in the UK is now slowing, but as this report went to press, about 290,000 have been infected and 40,000 have died from COVID-19 in hospitals.
The UK problem is not a shortage of intensive-care capacity. Hospitals have reorganized swiftly and seven new field hospitals have been hurriedly set up. Instead, the problems appear to have started earlier. The British government gave up quickly on the sort of test-and-isolate strategy common in countries that have kept deaths down. Its aim became simply to protect the vulnerable and the health service, accepting that the virus will spread among the population, which would at least build herd immunity.
Before COVID-19 hit, the PM plan was to “level up” poorer communities. The opposite is happening. Young and old, all have markedly different capacities to bear the burden of lockdown, social isolation and a sharp decline in economic activity.
The July 4th reopening indicates the UK government’s despair to give a boost to the economy. The infected reproduction number has stayed below one, and the number of people admitted to hospital and testing positive has continued to fall (although not yet to levels seen in the rest of Europe).
The UK scientific advisory committee examined two alternatives for action: another phased reopening or a big bang. The PM fell for the latter. He seems to have been out in front of the citizens who, opinion poll indicated, favor ending the lockdown.
Yet the great reopening is yet a gamble. A lot depends on the constraints that will stay put in place, and the new contact-tracing technology. Although the supplementary applications will not appear until winter, human contact-tracers have begun work.
 |
The UK COVID-19 Market Segmentation Vectors
6 End User and 4 Revenue Source Markets:
 |
29 Products and Services Markets:
 |
The UK’s COVID-19 pandemic mitigation products market is driven by the demand for the following:
- On the backdrop of the first and second surge of the pandemic by early 2020, and the removal of the lockdown, the UK healthcare establishment invests billions to mitigate the next wave of the pandemic
- The growing size of coronavirus related information and mounting complications of datasets, and the need saved by financial resources
- Advanced AI and machine learning have a high demand among general practitioners and others who are not coronavirus ICU experts
- the United Kingdom pharma and biotech companies research and development of coronavirus vaccines and medications
- The growing size of coronavirus related information and mounting complications of datasets, and the need saved by financial resources
- The UK pharma and biotech companies research and development of coronavirus vaccines and medications
and demand for:
- Serologic Tests
- COVID-19 Vaccines
- Ventilators
- Electronic Contact Tracing
- Surge Hospitals
- Training of ICU and ER personnel
- Strategic National Stockpile
- Pandemic related turnkey manufacturing plants
- PCR tests
- PPE
- Invasive ventilators
- New ICU units
- COVID-19 medications
- COVID-19 Informatics
- COVID-19 medical imaging services
This 420 -page market report is the most comprehensive review of the UK COVID-19 market available today. The objective of this report is to provide today’s strategic decision-makers with an expert 360-degree, time-sensitive, detailed view of this interconnected market.
The UK COVID-19 Pandemic Mitigation Products Market – 2020-2024 report presents a thorough market analysis of 29 products & services, 6 end users, 4 revenue source markets. Furthermore, the report provides updated extensive data of 37 key vendors.
Why Buy this UK COVID-19 Pandemic Mitigation Products Market Report?
A. Questions answered in this report include:
- What is the UK COVID-19 Market size and what are the forecast trends during 2020-2024?
- What are the most attractive business opportunities?
- What drives the customers to purchase solutions and services?
- What are the UK COVID-19 Market trends?
- What are the challenges to market penetration & growth?
B. The UK COVID-19 market size data is analyzed via 5 independent key perspectives. With a highly fragmented market we address the “money trail” – each dollar spent in the UK COVID-19 market is analyzed and crosschecked via 3 orthogonal viewpoints:
- By 29 Products and Services:
|
|
- By 6 End User Markets:
|
- By 4 Revenue Source Markets:
|
C. Detailed market analysis frameworks for each of the market sectors are provided, including:
|
D. The report provides an updated extensive data of the leading 37 companies (including companies’ profile, recent annual revenues, COVID-19 mitigation activities & products and contact information).
E. The report includes over 2300 links to the COVID-19 pandemic mitigation community information sources
F. The report mentions > 450 Vendors including the following:
Moderna, IBM, 3M Company, Philips NV, Johnson & Johnson, Roche, Nvidia Corporation, Thermo Fisher Scientific, Siemens, Toshiba, Google, Samsung Electronics Co, GE Healthcare, Medtronic, MedWhat, MedyMatch, Merck, Metabiota, Micron Technology, Infermedica, Infervision, Inovio Pharmaceuticals, Microsoft Corporation, Mindshare Medical, Morpheo, Pfizer, Philips NV, Maxim Biotech, Honeywell Safety Products, Philips Healthcare, Siemens, Recursion Pharmaceuticals, Fujifilm Holdings Corporation, 3Scan, Abbott , AbCellera, Advenio Technosys, Agfa Healthcare, Agilent Technologies, AiCure, Aindra, Allscripts Healthcare Solutions, Amara Health Analytics, Amazon , analyticsMD, Apixio, Apple, Arterys Inc., Atlas Wearables, Atomwise, Avalon Nutrition VITL, Babylon Health, Bay Labs, Behold.ai, benevolent.ai, BIOBEATS, BlueDot, Bollé Safety, Bullard, Buoy Health, Care Angel Wearables QorQL, Careskore, Clinithink, Cloud Pharmaceuticals, CloudMedx, CureMetrix Mental health Ginger.io, Cyrcadia, Deep 6 AI, Deep Genomics, Dell Technologies Inc., Delta Plus Group, Desktop Genetics Virtual mate Ada Health, DreaMed Diabetes, Dupont, EaglEyeMed, Eli Lilly, Encon Safety Products, Enlitic, EnsoData, Entopsis, Envisagenics Research iCarbonX, ERB Industries Inc., Ergodyne, Essilor of America, Flashback Technologies, Flow Health, Ford, Freenome, Frequency Therapeutics Inc., Gateway Safety Inc., General Motors, General Vision, Gentex Corporation, Gibco, Gilead Sciences, Globavir Biosciences, Healint, Health Fidelity, HealthNextGen, HexArmor, Hindsait, Imagen Technologies, Imagia Cybernetics, Inside DNA, InSilico Medicine, Intel Corporation, Intendu, Invitrogen, Ion Torrent, Ironwear, Jvion, Kapa Biosystems, Keen Eye Technologies, Kimberly-Clark Professional, Lexmark International Inc., LifeGraph, Lucina Health, Lumiata, Lunit, Lytics, Magnea, Maxwell MRI, McKesson Corporation, MCR Safety, Medal, Medalogix, Medasense, MedAware, Niramai Health Analytix, Novarad Corporation, NuMedii, Numerate, Nuritas Pharma Turbine, Oncora Medical, Ovuline, PeerWell, PhysIQ, Precision Health Intelligence, Predible Health, Profility, Proscia, pulseData, Pyramex Safety, Qualaris Healthcare Solutions, Qualcomm Incorporated, Qualcomm Incorporated, Qure.Ai, Radians Inc., Roam Analytics, RxPREDICT, Safety Optical Service Ltd, Sanofi, Saykara, Sellstrom Manufacturing Company (SureWerx), Sense.ly, Sensory Inc., Sigma-Aldrich Corp., Skymind Inc., Vir Biotechnology Inc., VisionAid Inc., WuXi Biologics, Xilinx Inc. and more.
G. UK COVID-19 market report includes 5 appendices:
- Appendix 1: Differences & Similarities between Common Flu and Coronavirus
- Appendix 2: COVID-19 Tests
- Appendix 3: Abbreviations
- Appendix 4: Glossary
- Appendix 5: Bibliography
COVID-19 pandemic mitigation market research team
The team which composed this report brings 43 years of hands on record in the development and commercialization of healthcare products including: antibody antigen identification, E-health, decontamination and biosecurity, PACS, teleradiology, PPE, computerized tomography, ultrasound, electron microscopy, medical devices and more. Our team members bring long term relations with the U.S. FDA and CDC as well as the EU CE and other national medical regulatory agencies.
As early as January 20, 2020 we recruited all our analysts to research the COVID-19 pandemic mitigation related products purchases. We interviewed hundreds of experts, participated in more than 95 conferences and webinars, reviewed more than 1,500 publications and interviewed executives of more than 65 pandemic related companies.
